Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.

Molecular pharmacology - 1 Oct 1994

Nitiss J L, Vilalta P M, Wu H, McMahon J

Abstract excerpt

Anti-topoisomerase II agents represent a major class of anticancer therapeutic agents. Resistance to this class of agents can be mediated by several possible mechanisms. One mechanism may involve mutations in the structural gene(s) for topoisomerases, altering the drug sensitivity of the enzymes. Several mutations have been described in mammalian cell lines that were selected for resistance to topoisomerase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to Base Sequence
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glycine

Share to Molecular Sequence Data

Share to Mutation

Share to Oligodeoxyribonucleotides

Share to Saccharomyces cerevisiae

Source

Identifiers

PMID: 7969059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.PMID 7969059Read ↗

Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.Semantic proximity Read ↗

Using yeast to study resistance to topoisomerase II-targeting drugs.Semantic proximity Read ↗

Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.Semantic proximity Read ↗

Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.Semantic proximity Read ↗

Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast.Semantic proximity Read ↗

Roles of nonhomologous end-joining pathways in surviving topoisomerase II–mediated DNA damageSemantic proximity Read ↗

Yeast as a genetic model system for studying topoisomerase inhibitors.Semantic proximity Read ↗

Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs.Semantic proximity Read ↗

Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.Semantic proximity Read ↗

The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.Semantic proximity Read ↗

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.Semantic proximity Read ↗

DNA repair functions that control sensitivity to topoisomerase-targeting drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.